 Shares of Theravance Biopharma Inc. TBPH, 0.85 fell more than 20 in the extended session Monday after the biopharmaceutical company said that a dose-finding study of one of its drugs, izencitinib, didnt measure up to a placebo in the treatment of ulcerative colitis. The company said it will look at the data to better understand findings and potential for the drug. 